Biogenerics Bill From Pallone/Deal Is A Mere 98 Questions Away From Consensus
Executive Summary
House Energy & Commerce Health Subcommittee staffers will need an extra-large spread sheet to find the consensus in stakeholder positions on follow-on biologics legislation
You may also be interested in...
Frank Torti’s Next 100 Days: Active, Not Just Acting FDA Commissioner
Frank Torti might not be in charge of FDA for very long, but he seems determined to make his time count
Torti's Next Hundred Days: Active, Not Just Acting FDA Commissoner
FDA's Chief Scientist will continue to push for outside academic collaborations during his "short time" atop the agency; fall letter on follow-on biologics could draw closer reading.
Most Biosimilars Would Need Clinical Trials, ASCO Tells House Panel
While urging Congress to write legislation that allows FDA to decide which scientific data are needed to approve follow-on biologics, comments from the American Society of Clinical Oncology to a House subcommittee note that clinical trials will be necessary for most FOBs